Anti‐tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Communications |
| Online Access: | https://doi.org/10.1002/cac2.12630 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589693109141504 |
|---|---|
| author | Ling Tang Yuanyuan Song Hong Zhang Ruimin Hao Xin Tong Xing Ai Jun Ma Zhimin Yang |
| author_facet | Ling Tang Yuanyuan Song Hong Zhang Ruimin Hao Xin Tong Xing Ai Jun Ma Zhimin Yang |
| author_sort | Ling Tang |
| collection | DOAJ |
| format | Article |
| id | doaj-art-4c1e58be7fff4f828767967d462e7ea0 |
| institution | Kabale University |
| issn | 2523-3548 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Communications |
| spelling | doaj-art-4c1e58be7fff4f828767967d462e7ea02025-01-24T09:09:47ZengWileyCancer Communications2523-35482025-01-01451636710.1002/cac2.12630Anti‐tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standardsLing Tang0Yuanyuan Song1Hong Zhang2Ruimin Hao3Xin Tong4Xing Ai5Jun Ma6Zhimin Yang7Office of Clinical Trial Management, Center for Drug Evaluation, National Medical Products Administration Beijing P. R. ChinaOffice of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration Beijing P. R. ChinaOffice of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration Beijing P. R. ChinaOffice of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration Beijing P. R. ChinaOffice of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration Beijing P. R. ChinaOffice of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration Beijing P. R. ChinaHarbin Institute of Hematology and Oncology Harbin Heilongjiang P. R. ChinaCenter for Drug Evaluation, National Medical Products Administration Beijing P. R. Chinahttps://doi.org/10.1002/cac2.12630 |
| spellingShingle | Ling Tang Yuanyuan Song Hong Zhang Ruimin Hao Xin Tong Xing Ai Jun Ma Zhimin Yang Anti‐tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards Cancer Communications |
| title | Anti‐tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards |
| title_full | Anti‐tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards |
| title_fullStr | Anti‐tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards |
| title_full_unstemmed | Anti‐tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards |
| title_short | Anti‐tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards |
| title_sort | anti tumor drug supervision in china from 2010 to 2024 the evolution and prospect of drug review standards |
| url | https://doi.org/10.1002/cac2.12630 |
| work_keys_str_mv | AT lingtang antitumordrugsupervisioninchinafrom2010to2024theevolutionandprospectofdrugreviewstandards AT yuanyuansong antitumordrugsupervisioninchinafrom2010to2024theevolutionandprospectofdrugreviewstandards AT hongzhang antitumordrugsupervisioninchinafrom2010to2024theevolutionandprospectofdrugreviewstandards AT ruiminhao antitumordrugsupervisioninchinafrom2010to2024theevolutionandprospectofdrugreviewstandards AT xintong antitumordrugsupervisioninchinafrom2010to2024theevolutionandprospectofdrugreviewstandards AT xingai antitumordrugsupervisioninchinafrom2010to2024theevolutionandprospectofdrugreviewstandards AT junma antitumordrugsupervisioninchinafrom2010to2024theevolutionandprospectofdrugreviewstandards AT zhiminyang antitumordrugsupervisioninchinafrom2010to2024theevolutionandprospectofdrugreviewstandards |